eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Additional Topic(s)
    Intraperitoneal infusion
  6. Additional Topic(s)
    Intravenous infusion
  7. Additional Topic(s)
    Progression-free survival
  8. Resource Description
    The purpose of this study is to determine if one or both of the proposed intraperitoneal chemotherapy regimens improves the progression-free survival (PFS) event rate compared to standard intravenous chemotherapy for first-line treatment of patients diagnosed with advanced stage ovarian, peritoneal or fallopian tube cancer. If both IP regimens significantly improve the PFS event rate compared to the standard regimen, then a second study objective is to determine whether IP cisplatin and IV paclitaxel on day one plus IP paclitaxel on day eight improves the PFS event rate when compared to the IP carboplatin and IV paclitaxel.
  9. Contact
    Berenberg, Jeffrey
  10. PI
    Berenberg, Jeffrey
  11. Topic
    peritoneal carcinoma
  12. Topic
    fallopian tube cancer
  13. Topic
    ovarian cancer
  14. Study Population
    Females aged 18 and older with histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma.
  15. Website(s)
  16. Funded by
    Gynecologic Oncology Group
  17. Phase
    Phase 3 clinical trial
  18. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016